These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 19911420

  • 1. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation.
    Iguchi A, Kobayashi R, Kaneda M, Kobayashi K.
    Pediatr Blood Cancer; 2010 Mar; 54(3):437-43. PubMed ID: 19911420
    [Abstract] [Full Text] [Related]

  • 2. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
    Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, Maruyama I.
    Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
    [Abstract] [Full Text] [Related]

  • 3. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H, Hiruma K, Matsunaga T, Morita T, Sakamaki H.
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [Abstract] [Full Text] [Related]

  • 4. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, Hirabayashi N.
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [Abstract] [Full Text] [Related]

  • 5. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
    Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR.
    Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
    [Abstract] [Full Text] [Related]

  • 6. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, Strugo L, Destro R, Gazzola MV, Varotto S, Errigo G, Carli M, Zanesco L, Messina C.
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [Abstract] [Full Text] [Related]

  • 7. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ, Spanish Myeloma Group/PETHEMA.
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [Abstract] [Full Text] [Related]

  • 8. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma.
    Horn B, Reiss U, Matthay K, McMillan A, Cowan M.
    Bone Marrow Transplant; 2002 Mar; 29(5):409-15. PubMed ID: 11919731
    [Abstract] [Full Text] [Related]

  • 9. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
    Pihusch M, Wegner H, Goehring P, Salat C, Pihusch V, Andreesen R, Kolb HJ, Holler E, Pihusch R.
    Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
    [Abstract] [Full Text] [Related]

  • 10. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, Ash RC, Champlin RE, Henslee-Downey PJ, Herzig RH, Hinterberger W, Klein JP, Prentice HG, Reiffers J, Zwaan FE, Horowitz MM.
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [Abstract] [Full Text] [Related]

  • 11. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.
    Batsis I, Yannaki E, Kaloyannidis P, Sakellari I, Smias C, Georgoulis I, Fassas A, Anagnostopoulos A.
    Thromb Res; 2006 Jan; 118(5):611-8. PubMed ID: 16330084
    [Abstract] [Full Text] [Related]

  • 12. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation.
    Park YD, Yoshioka A, Kawa K, Ishizashi H, Yagi H, Yamamoto Y, Matsumoto M, Fujimura Y.
    Bone Marrow Transplant; 2002 May; 29(9):789-94. PubMed ID: 12040478
    [Abstract] [Full Text] [Related]

  • 13. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D.
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [Abstract] [Full Text] [Related]

  • 14. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
    Salat C, Holler E, Göhring P, Poley S, Kolb HJ, Pihusch R, Reinhardt B, Krämling HJ, Haller M, Hiller E.
    Eur J Med Res; 1996 Nov 25; 1(12):571-4. PubMed ID: 9438165
    [Abstract] [Full Text] [Related]

  • 15. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F, Sanz GF, de La Rubia J, Jiménez C, Saavedra S, Regadera A, Andreu R, García I, Plumé G, Martínez J, Martín G, Jarque I, Sanz MA.
    Bone Marrow Transplant; 2001 May 25; 27(9):983-8. PubMed ID: 11436110
    [Abstract] [Full Text] [Related]

  • 16. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A, Marshall L, Lancaster D.
    Pediatr Blood Cancer; 2008 Apr 25; 50(4):831-2. PubMed ID: 18286502
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Cairo MS.
    Bone Marrow Transplant; 1996 Jul 25; 18(1):185-91. PubMed ID: 8832013
    [Abstract] [Full Text] [Related]

  • 18. TIPS for veno-occlusive disease following stem cell transplantation.
    Schoppmeyer K, Lange T, Wittekind C, Niederwieser D, Caca K.
    Z Gastroenterol; 2006 Jun 25; 44(6):483-6. PubMed ID: 16773513
    [Abstract] [Full Text] [Related]

  • 19. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G.
    Bone Marrow Transplant; 2001 Oct 25; 28(8):743-51. PubMed ID: 11781625
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
    Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, Chan GC.
    Bone Marrow Transplant; 2007 Nov 25; 40(10):935-44. PubMed ID: 17768390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.